@uabnews and @DiamondThera have announced a collaboration, researching low doses of psilocybin to treat demoralization. @uabsoph professor Peter Hendricks, PhD is principle investigator in this five-week randomized clinical trial. Read more at https://t.co/BFHglJkMGI
Diamond is excited to announce our FDA-authorized clinical trial of low-dose psilocybin in collaboration with the University of Alabama at Birmingham.
https://t.co/C0nkavO78d
“Anxiety is the most common psychiatric disorder,” says Judy Blumstock, Diamond’s chief executive. “And the existing treatments aren’t satisfactory.” https://t.co/wciDckypVU
Today is #BellLetsTalk Day! One of the ways we can all take action is to learn about mental health organizations creating positive change for mental health in Canada…every day.
Diamond’s Phase 2 trial has been approved by Health Canada, a Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder. Patients will receive repeat low doses of psilocybin administered on a take-home basis.
@DiamondThera
https://t.co/wcTnCex610
Diamond has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low doses of psilocybin for the treatment of generalized anxiety disorder (GAD). https://t.co/9WCuT6vcyH
“The purpose of this endowment is to support a professorship and to establish a world class, rigorous, empirical program of research with psychedelic substances..”https://t.co/qrlKlBhXii
The 2022 OBI GEEKs have been chosen! First up, we have Health Nexus Santé: The Indigenous Brain Story creating a revised curriculum for brain neuroscience training. Learn more about the 2022 GEEKs here > https://t.co/Pk1P25HI8N
#meettheGEEKs#indigenousbrainhealth#community
New episode: Microdosing (Part 3)!
We discuss the path to FDA approval with...
Dr. Dan Karlin: MindMed (LSD for adult ADHD)
and
Dr. Mike McDonnell: Diamond Therapeutics (psilocybin for anxiety disorders)
Tune in here: https://t.co/cfdBV3ZXF9
@mindmedco@DiamondThera
For those looking for more information about psychedelics and psychedelic therapy, check out the Berkeley Center’s new resources website, https://t.co/6K1TfYHecy
In part 2 (out next week), we discuss the placebo effect and results from a placebo controlled microdosing study from @psybalazs@imperialcollege.
In part 3, we talk w/ the chief medical officers of @mindmedco@DiamondThera about going for FDA approval for microdosing.
5/5
@DiamondThera science advisory chair Dr. Ed Sellers outlines the challenges of testing #psychedelics in human subjects in the International Journal of Pharmacology’s special issue on psychedelic science. https://t.co/hMj4rYVzOf
4/5 In this episode of @ProfDavidNutt's @Drug_Science
Podcast, @DiamondThera advisor Dr. Paul Glue discusses the development of oral ketamine and his hope that it can become an at-home vs. in-clinic treatment. https://t.co/ss9Xjejs0D